KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBIT Margin: 2009-2025

Historic EBIT Margin for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to 27.35%.

  • Regeneron Pharmaceuticals' EBIT Margin fell 435.00% to 27.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.89%, marking a year-over-year decrease of 281.00%. This contributed to the annual value of 28.10% for FY2024, which is 275.00% down from last year.
  • Regeneron Pharmaceuticals' EBIT Margin amounted to 27.35% in Q3 2025, which was down 6.88% from 29.37% recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EBIT Margin ranged from a high of 2,517.00% in Q1 2022 and a low of 19.54% during Q1 2025.
  • Moreover, its 3-year median value for EBIT Margin was 29.37% (2025), whereas its average is 28.33%.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 247,300bps in 2022, then plummeted by 248,706bps in 2023.
  • Regeneron Pharmaceuticals' EBIT Margin (Quarterly) stood at 53.31% in 2021, then spiked by 109,349bps to 1,146.80% in 2022, then plummeted by 111,847bps to 28.33% in 2023, then tumbled by 220bps to 26.13% in 2024, then tumbled by 435bps to 27.35% in 2025.
  • Its last three reported values are 27.35% in Q3 2025, 29.37% for Q2 2025, and 19.54% during Q1 2025.